{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:06:57Z","timestamp":1793387217241,"version":"4.5.0"},"reference-count":125,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genome Ed."],"abstract":"<jats:p>Hepatitis B virus (HBV) infection is a common cause of liver disease worldwide. The current antiviral treatment using nucleotide analogues (NAs) can only suppress <jats:italic>de novo<\/jats:italic> HBV replication but cannot eliminate chronic HBV infection due to the persistence of covalently closed circular (ccc) DNA that sustains viral replication. The CRISPR\/Cas9 system is a novel genome-editing tool that enables precise gene disruption and inactivation. With high efficiency and simplicity, the CRISPR\/Cas9 system has been utilized in multiple studies to disrupt the HBV genome specifically, eliciting varying anti-HBV effects both <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. Additionally, multi-locus gene targeting has shown enhanced antiviral activity, paving the way for combination therapy to disrupt and inactivate HBV cccDNA as well as integrated HBV DNA. Despite its promising antiviral effects, this technology faces several challenges that need to be overcome before its clinical application, i.e., off-target effects and <jats:italic>in vivo<\/jats:italic> drug delivery. As such, there is a need for improvement in CRISPR\/Cas9 efficiency, specificity, versatility, and delivery. Here, we critically review the recent literature describing the tools employed in designing guide RNAs (gRNAs) targeting HBV genomes, the vehicles used for expressing and delivering CRISPR\/Cas9 components, the models used for evaluating CRISPR-mediated HBV gene disruption, the methods used for assessing antiviral and off-target effects induced by CRISPR\/Cas9-mediated HBV gene disruption, and the prospects of future directions and challenges in leveraging this HBV gene-editing approach, to advance the HBV treatment toward a clinical cure.<\/jats:p>","DOI":"10.3389\/fgeed.2024.1467449","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T04:53:49Z","timestamp":1728449629000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["The potential of HBV cure: an overview of CRISPR-mediated HBV gene disruption"],"prefix":"10.3389","volume":"6","author":[{"given":"Zhi Q.","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison B.","family":"Schank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El Gazzar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addison C.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puja","family":"Banik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeden S.","family":"Pyburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.","family":"Moorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3390\/v9060156","article-title":"The role of cccDNA in HBV maintenance","volume":"9","author":"Allweiss","year":"2017","journal-title":"Viruses"},{"key":"B2","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1136\/gutjnl-2022-328380","article-title":"Quantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cure","volume":"72","author":"Allweiss","year":"2023","journal-title":"Gut"},{"key":"B3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1365-2613.2001.iep0082-0077-x","article-title":"Hepatitis B virus and hepatocellular carcinoma","volume":"82","author":"Arbuthnot","year":"2001","journal-title":"Int. J. Exp. Pathology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.celrep.2017.06.064","article-title":"CRISPR-mediated integration of large gene cassettes using AAV donor vectors","volume":"20","author":"Bak","year":"2017","journal-title":"Cell. Rep."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e1004090","DOI":"10.1371\/journal.ppat.1004090","article-title":"High-efficiency targeted editing of large viral genomes by RNA-guided nucleases","volume":"10","author":"Bi","year":"2014","journal-title":"PLoS Pathog."},{"key":"B6","doi-asserted-by":"publisher","first-page":"799722","DOI":"10.3389\/fgeed.2021.799722","article-title":"The role of recombinant AAV in precise genome editing","volume":"3","author":"Bijlani","year":"2022","journal-title":"Front. Genome Ed."},{"key":"B7","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1172\/JCI40094","article-title":"Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment","volume":"120","author":"Bissig","year":"2010","journal-title":"J. Clin. Investigation"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1038\/mt.2013.170","article-title":"Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases","volume":"21","author":"Bloom","year":"2013","journal-title":"Mol. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/nmeth.4284","article-title":"Mapping the genomic landscape of CRISPR\u2013Cas9 cleavage","volume":"14","author":"Cameron","year":"2017","journal-title":"Nat. Methods"},{"key":"B10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1440-1746.2010.06514.x","article-title":"JGH Foundation emerging leadership lecture. Significance of hepatitis B virus genotypes and mutations in the development of hepatocellular carcinoma in Asia","volume":"26","author":"Chan","year":"2011","journal-title":"J. Gastroenterology Hepatology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41565-019-0539-2","article-title":"A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing","volume":"14","author":"Chen","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/mt.2013.212","article-title":"An efficient antiviral strategy for targeting hepatitis B virus genome using transcription activator-like effector nucleases","volume":"22","author":"Chen","year":"2014","journal-title":"Mol. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1101\/gr.162339.113","article-title":"Analysis of off-target effects of CRISPR\/Cas-derived RNA-guided endonucleases and nickases","volume":"24","author":"Cho","year":"2014","journal-title":"Genome Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"W242-W245","DOI":"10.1093\/nar\/gky354","article-title":"CRISPOR: intuitive guide selection for CRISPR\/Cas9 genome editing experiments and screens","volume":"46","author":"Concordet","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/nm.3793","article-title":"Therapeutic genome editing: prospects and challenges","volume":"21","author":"Cox","year":"2015","journal-title":"Nat. Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/mt.2010.20","article-title":"Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs","volume":"18","author":"Cradick","year":"2010","journal-title":"Mol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"289","DOI":"10.4254\/wjh.v7.i3.289","article-title":"Genotypes and viral variants in chronic hepatitis B: a review of epidemiology and clinical relevance","volume":"7","author":"Croagh","year":"2015","journal-title":"World J. Hepatology"},{"key":"B19","doi-asserted-by":"publisher","first-page":"3873","DOI":"10.2147\/IDR.S240472","article-title":"cccDNA maintenance in chronic hepatitis B \u2013 targeting the matrix of viral replication","volume":"13","author":"Dandri","year":"2020","journal-title":"Infect. Drug Resist."},{"key":"B20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","article-title":"Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9","volume":"34","author":"Doench","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.antiviral.2015.03.015","article-title":"Targeting hepatitis B virus cccDNA by CRISPR\/Cas9 nuclease efficiently inhibits viral replication","volume":"118","author":"Dong","year":"2015","journal-title":"Antivir. Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1258096","DOI":"10.1126\/science.1258096","article-title":"Genome editing. The new frontier of genome engineering with CRISPR-Cas9","volume":"346","author":"Doudna","year":"2014","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/liv.14371","article-title":"Will we need novel combinations to cure HBV infection?","volume":"40","author":"Dusheiko","year":"2020","journal-title":"Liver Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1038\/srep02510","article-title":"Harnessing the CRISPR\/Cas9 system to disrupt latent HIV-1 provirus","volume":"3","author":"Ebina","year":"2013","journal-title":"Sci. Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B26","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/sj.gt.3302233","article-title":"Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors","volume":"11","author":"Flotte","year":"2004","journal-title":"Gene Ther."},{"key":"B27","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1093\/nar\/gkg563","article-title":"ExPASy: the proteomics server for in-depth protein knowledge and analysis","volume":"31","author":"Gasteiger","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"B30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.antiviral.2015.06.008","article-title":"Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities","volume":"121","author":"Gish","year":"2015","journal-title":"Antivir. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"15655","DOI":"10.1073\/pnas.232137699","article-title":"Infection of a human hepatoma cell line by hepatitis B virus","volume":"99","author":"Gripon","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.antiviral.2015.08.005","article-title":"Metabolism and function of hepatitis B virus cccDNA: implications for the development of cccDNA-targeting antiviral therapeutics","volume":"122","author":"Guo","year":"2015","journal-title":"Antivir. Res."},{"key":"B33","first-page":"95","article-title":"BioEdit: a user-friendly biological sequence alignment editor and analysis program for windows 95\/98\/NT","volume":"41","author":"Hall","year":"1999","journal-title":"Nucleic acids symp. Ser."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/s41598-022-05882-9","article-title":"Droplet digital PCR assay provides intrahepatic HBV cccDNA quantification tool for clinical application","volume":"12","author":"Hayashi","year":"2022","journal-title":"Sci. Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and applications of CRISPR-cas9 for genome engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell."},{"key":"B36","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nbt.2647","article-title":"DNA targeting specificity of RNA-guided Cas9 nucleases","volume":"31","author":"Hsu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41596-018-0069-7","article-title":"CRISPR\u2013Cas9 genome engineering of primary CD4+ T cells for the interrogation of HIV\u2013host factor interactions","volume":"14","author":"Hultquist","year":"2019","journal-title":"Nat. Protoc."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-022-00342-5","article-title":"Prospects of viral vector-mediated delivery of sequences encoding anti-HBV designer endonucleases","author":"Jacobs","year":"2022","journal-title":"Gene Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/cr.2017.16","article-title":"A non-viral CRISPR\/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo","volume":"27","author":"Jiang","year":"2017","journal-title":"Cell. Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-biophys-062215-010822","article-title":"CRISPR\u2013Cas9 structures and mechanisms","volume":"46","author":"Jiang","year":"2017","journal-title":"Annu. Rev. Biophysics"},{"key":"B41","doi-asserted-by":"publisher","first-page":"eaau6977","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature22341","article-title":"Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer","volume":"546","author":"Kamerkar","year":"2017","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","first-page":"13734","DOI":"10.1038\/srep13734","article-title":"CRISPR\/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X","volume":"5","author":"Karimova","year":"2015","journal-title":"Sci. Rep."},{"key":"B44","doi-asserted-by":"publisher","first-page":"198191","DOI":"10.1016\/j.virusres.2020.198191","article-title":"Development of an in vivo delivery system for CRISPR\/Cas9-mediated targeting of hepatitis B virus cccDNA","volume":"290","author":"Kayesh","year":"2020","journal-title":"Virus Res."},{"key":"B45","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.virol.2014.12.001","article-title":"Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR\/Cas RNA-guided DNA endonuclease","volume":"476","author":"Kennedy","year":"2015","journal-title":"Virology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.3390\/v14091902","article-title":"Synthetic gRNA\/cas9 ribonucleoprotein inhibits HIV reactivation and replication","volume":"14","author":"Khanal","year":"2022","journal-title":"Viruses"},{"key":"B47","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jconrel.2017.09.013","article-title":"Cancer-derived exosomes as a delivery platform of CRISPR\/Cas9 confer cancer cell tropism-dependent targeting","volume":"266","author":"Kim","year":"2017","journal-title":"J. Control. Release"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.jhep.2018.08.012","article-title":"Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels","volume":"69","author":"Ko","year":"2018","journal-title":"J. Hepatology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"475","DOI":"10.14348\/molcells.2015.0103","article-title":"Measuring and reducing off-target activities of programmable nucleases including CRISPR-cas9","volume":"38","author":"Koo","year":"2015","journal-title":"Mol. Cells"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s00018-019-03021-8","article-title":"Orthologous CRISPR\/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus","volume":"76","author":"Kostyushev","year":"","journal-title":"Cell. Mol. Life Sci."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1038\/s41598-019-38526-6","article-title":"Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR\/Cas9","volume":"9","author":"Kostyushev","year":"","journal-title":"Sci. Rep."},{"key":"B52","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1134\/S0026898419010075","article-title":"Small molecular inhibitors of DNA double strand break repair pathways increase the ANTI-HBV activity of CRISPR\/Cas9","volume":"53","author":"Kostyusheva","year":"2019","journal-title":"Mol. Biol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrgastro.2011.33","article-title":"Hepatitis B therapy","volume":"8","author":"Kwon","year":"2011","journal-title":"Nat. Rev. Gastroenterology and Hepatology"},{"key":"B54","doi-asserted-by":"publisher","first-page":"W171-W174","DOI":"10.1093\/nar\/gkz365","article-title":"CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing","volume":"47","author":"Labun","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1128\/AAC.41.8.1715","article-title":"Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication","volume":"41","author":"Ladner","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"B56","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jhep.2009.05.022","article-title":"Control of cccDNA function in hepatitis B virus infection","volume":"51","author":"Levrero","year":"2009","journal-title":"J. Hepatology"},{"key":"B57","first-page":"267","article-title":"Studying HBV infection and therapy in immune-deficient NOD-Rag1-\/-IL2RgammaC-null (NRG) fumarylacetoacetate hydrolase (Fah) knockout mice transplanted with human hepatocytes","volume-title":"Methods Mol. Biol.","author":"Li","year":""},{"key":"B58","first-page":"109","article-title":"Cell culture models and animal models for HBV study","volume-title":"Adv. Exp. Med. Biol.","author":"Li","year":"2020"},{"key":"B59","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.cmi.2014.10.007","article-title":"Whole genome characterization of hepatitis B virus quasispecies with massively parallel pyrosequencing","volume":"21","author":"Li","year":"2015","journal-title":"Clin. Microbiol. Infect."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.7150\/ijbs.16064","article-title":"An effective molecular target site in hepatitis B virus S gene for Cas9 cleavage and mutational inactivation","volume":"12","author":"Li","year":"2016","journal-title":"Int. J. Biol. Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.3389\/fimmu.2018.02080","article-title":"Inhibition of HBV expression in HBV transgenic mice using AAV-delivered CRISPR-SaCas9","volume":"9","author":"Li","year":"","journal-title":"Front. Immunol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fcimb.2017.00091","article-title":"Removal of integrated hepatitis B virus DNA using CRISPR-cas9","volume":"7","author":"Li","year":"","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.biomaterials.2018.04.031","article-title":"Non-viral delivery systems for CRISPR\/Cas9-based genome editing: challenges and opportunities","volume":"171","author":"Li","year":"","journal-title":"Biomaterials"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1002\/hep.28025","article-title":"Present and future therapies of hepatitis B: from discovery to cure","volume":"62","author":"Liang","year":"2015","journal-title":"Hepatology"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1038\/mtna.2014.38","article-title":"The CRISPR\/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo","volume":"3","author":"Lin","year":"2014","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1700611","DOI":"10.1002\/advs.201700611","article-title":"Exosome\u2013liposome hybrid nanoparticles deliver CRISPR\/Cas9 system in MSCs","volume":"5","author":"Lin","year":"2018","journal-title":"Adv. Sci."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1099\/vir.0.000159","article-title":"Inhibition of hepatitis B virus by the CRISPR\/Cas9 system via targeting the conserved regions of the viral genome","volume":"96","author":"Liu","year":"2015","journal-title":"J. General Virology"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.3390\/v13122461","article-title":"Transient CRISPR-cas treatment can prevent reactivation of HIV-1 replication in a latently infected T-cell line","volume":"13","author":"Liu","year":"2021","journal-title":"Viruses"},{"key":"B69","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.antiviral.2018.02.011","article-title":"Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from Staphylococcus aureus","volume":"152","author":"Liu","year":"2018","journal-title":"Antivir. Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"S41-S48","DOI":"10.1016\/j.jhep.2016.02.009","article-title":"Attacking hepatitis B virus cccDNA \u2013 the holy grail to hepatitis B cure","volume":"64","author":"Lucifora","year":"2016","journal-title":"J. Hepatology"},{"key":"B71","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/COH.0000000000000623","article-title":"Recent developments with advancing gene therapy to treat chronic infection with hepatitis B virus","volume":"15","author":"Maepa","year":"2020","journal-title":"Curr. Opin. HIV AIDS"},{"key":"B72","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/nbt.2675","article-title":"CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering","volume":"31","author":"Mali","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e0136021","DOI":"10.1128\/JVI.01360-21","article-title":"Proteomic analysis of nuclear hepatitis B virus relaxed circular DNA-associated proteins identifies UV-damaged DNA binding protein as a host factor involved in covalently closed circular DNA formation","volume":"96","author":"Marchetti","year":"2022","journal-title":"J. Virology"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e0288821","DOI":"10.1128\/mbio.02888-21","article-title":"CRISPR-Cas9 targeting of hepatitis B virus covalently closed circular DNA generates transcriptionally active episomal variants","volume":"13","author":"Martinez","year":"2022","journal-title":"mBio"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e99263","DOI":"10.1172\/jci.insight.99263","article-title":"Generation and testing of clinical-grade exosomes for pancreatic cancer","volume":"3","author":"Mendt","year":"2018","journal-title":"JCI Insight"},{"key":"B76","doi-asserted-by":"publisher","first-page":"15178","DOI":"10.1038\/ncomms15178","article-title":"Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens","volume":"8","author":"Morgens","year":"2017","journal-title":"Nat. Commun."},{"key":"B77","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1021\/acs.bioconjchem.7b00057","article-title":"In vivo delivery of CRISPR\/Cas9 for therapeutic gene editing: progress and challenges","volume":"28","author":"Mout","year":"2017","journal-title":"Bioconjugate Chem."},{"key":"B78","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/hep4.2014","article-title":"Inhibition of nonhomologous end joining\u2010mediated DNA repair enhances anti\u2010HBV CRISPR therapy","volume":"6","author":"Murai","year":"2022","journal-title":"Hepatol. Commun."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"B80","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1146\/annurev-chembioeng-080615-034711","article-title":"Engineering delivery vehicles for genome editing","volume":"7","author":"Nelson","year":"2016","journal-title":"Annu. Rev. Chem. Biomol. Eng."},{"key":"B81","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41587-019-0325-6","article-title":"Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency","volume":"38","author":"Nguyen","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1093\/nar\/gkv137","article-title":"A genome-wide analysis of Cas9 binding specificity using ChIP-seq and targeted sequence capture","volume":"43","author":"O'Geen","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"B83","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jhep.2016.08.013","article-title":"Time trends of chronic HBV infection over prior decades - a global analysis","volume":"66","author":"Ott","year":"2017","journal-title":"J. Hepatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/nbt.2673","article-title":"High-throughput profiling of off-target DNA cleavage reveals RNA-programmed Cas9 nuclease specificity","volume":"31","author":"Pattanayak","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.jhep.2012.02.033","article-title":"Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy","volume":"57","author":"Peng","year":"2012","journal-title":"J. Hepatology"},{"key":"B86","doi-asserted-by":"publisher","first-page":"8045","DOI":"10.1128\/JVI.01024-14","article-title":"Recombinant covalently closed circular hepatitis B virus DNA induces prolonged viral persistence in immunocompetent mice","volume":"88","author":"Qi","year":"2014","journal-title":"J. Virology"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1016\/j.jmb.2020.02.026","article-title":"ProNA2020 predicts protein\u2013DNA, protein\u2013RNA, and protein\u2013protein binding proteins and residues from sequence","volume":"432","author":"Qiu","year":"2020","journal-title":"J. Mol. Biol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"10833","DOI":"10.1038\/srep10833","article-title":"CRISPR\/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus","volume":"5","author":"Ramanan","year":"2015","journal-title":"Sci. Rep."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","article-title":"Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity","volume":"154","author":"Ran","year":"2013","journal-title":"Cell."},{"key":"B90","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","article-title":"Reprogramming human T cell function and specificity with non-viral genome targeting","volume":"559","author":"Roth","year":"2018","journal-title":"Nature"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1111\/gtc.12437","article-title":"Highly multiplexed CRISPR\u2010Cas9\u2010nuclease and Cas9\u2010nickase vectors for inactivation of hepatitis B virus","volume":"21","author":"Sakuma","year":"2016","journal-title":"Genes. Cells"},{"key":"B92","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ymeth.2019.02.022","article-title":"Base editing the mammalian genome","author":"Schatoff","year":"2019","journal-title":"Methods"},{"key":"B93","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.omtn.2018.05.006","article-title":"One-vector system for multiplexed CRISPR\/Cas9 against hepatitis B virus cccDNA utilizing high-capacity adenoviral vectors","volume":"12","author":"Schiwon","year":"2018","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"B95","doi-asserted-by":"publisher","first-page":"7401","DOI":"10.1038\/s41598-017-07642-6","article-title":"ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells","volume":"7","author":"Scott","year":"2017","journal-title":"Sci. Rep."},{"key":"B96","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1038\/mtna.2014.68","article-title":"Targeting hepatitis B virus with CRISPR\/Cas9","volume":"3","author":"Seeger","year":"2014","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/mt.2016.94","article-title":"Complete spectrum of CRISPR\/Cas9-induced mutations on HBV cccDNA","volume":"24","author":"Seeger","year":"2016","journal-title":"Mol. Ther."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1073\/pnas.84.4.1005","article-title":"Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA","volume":"84","author":"Sells","year":"1987","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B99","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1038\/s41598-018-19441-8","article-title":"A survey of validation strategies for CRISPR-cas9 editing","volume":"8","author":"Sentmanat","year":"2018","journal-title":"Sci. Rep."},{"key":"B100","doi-asserted-by":"publisher","first-page":"m2200","DOI":"10.1136\/bmj.m2200","article-title":"Hepatitis B virus persistence and reactivation","volume":"370","author":"Shi","year":"2020","journal-title":"BMJ"},{"key":"B101","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.omtm.2018.06.006","article-title":"Prevalence of pre-existing antibodies to CRISPR-associated nuclease Cas9 in the USA population","volume":"10","author":"Simhadri","year":"2018","journal-title":"Mol. Ther. - Methods and Clin. Dev."},{"key":"B102","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ijid.2017.04.002","article-title":"Humanized chimeric mouse models of hepatitis B virus infection","volume":"59","author":"Sun","year":"2017","journal-title":"Int. J. Infect. Dis."},{"key":"B103","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jconrel.2020.12.013","article-title":"Lipid nanoparticles loaded with ribonucleoprotein-oligonucleotide complexes synthesized using a microfluidic device exhibit robust genome editing and hepatitis B virus inhibition","volume":"330","author":"Suzuki","year":"2021","journal-title":"J. Control Release"},{"key":"B104","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1053\/j.gastro.2014.02.024","article-title":"Identification of NTCP as an HBV receptor: the beginning of the end or the end of the beginning?","volume":"146","author":"Tong","year":"2014","journal-title":"Gastroenterology"},{"key":"B105","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","article-title":"High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population","volume":"25","author":"Wagner","year":"2019","journal-title":"Nat. Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"9554","DOI":"10.3748\/wjg.v21.i32.9554","article-title":"Dual gRNAs guided CRISPR\/Cas9 system inhibits hepatitis B virus replication","volume":"21","author":"Wang","year":"2015","journal-title":"World J. Gastroenterology"},{"key":"B107","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/gt.2016.72","article-title":"Non-viral delivery of genome-editing nucleases for gene therapy","volume":"24","author":"Wang","year":"2017","journal-title":"Gene Ther."},{"key":"B108","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1002\/hep.32245","article-title":"HBV covalently closed circular DNA minichromosomes in distinct epigenetic transcriptional states differ in their vulnerability to damage","volume":"75","author":"Wang","year":"2022","journal-title":"Hepatology"},{"key":"B109","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s41048-020-00112-z","article-title":"Epigenetic regulation of covalently closed circular DNA minichromosome in hepatitis B virus infection","volume":"6","author":"Wang","year":"2020","journal-title":"Biophys. Rep."},{"key":"B110","doi-asserted-by":"publisher","first-page":"20059","DOI":"10.1021\/acsomega.9b03245","article-title":"Biodegradable drug-delivery peptide nanocapsules","volume":"4","author":"Wessel","year":"2019","journal-title":"ACS Omega"},{"key":"B111","volume-title":"Hepatitis B","year":"2024"},{"key":"B112","doi-asserted-by":"publisher","first-page":"104824","DOI":"10.1016\/j.antiviral.2020.104824","article-title":"Hepatitis B virus cccDNA: formation, regulation and therapeutic potential","volume":"180","author":"Xia","year":"2020","journal-title":"Antivir. Res."},{"key":"B113","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12985-021-01580-6","article-title":"Advances in HBV infection and replication systems in vitro","volume":"18","author":"Xu","year":"2021","journal-title":"Virology J."},{"key":"B114","doi-asserted-by":"publisher","first-page":"W337","DOI":"10.1093\/nar\/gku366","article-title":"PredictProtein\u2014an open resource for online prediction of protein structural and functional features","volume":"42","author":"Yachdav","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"B115","doi-asserted-by":"publisher","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"eLife"},{"key":"B116","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.virusres.2017.06.010","article-title":"The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA","volume":"244","author":"Yang","year":"2018","journal-title":"Virus Res."},{"key":"B117","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.omtn.2020.03.005","article-title":"Permanent inactivation of HBV genomes by CRISPR\/Cas9-Mediated non-cleavage base editing","volume":"20","author":"Yang","year":"2020","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"B118","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1039\/d0bm00427h","article-title":"An engineered exosome for delivering sgRNA:Cas9 ribonucleoprotein complex and genome editing in recipient cells","volume":"8","author":"Ye","year":"2020","journal-title":"Biomaterials Sci."},{"key":"B119","doi-asserted-by":"publisher","first-page":"eabj8207","DOI":"10.1126\/sciadv.abj8207","article-title":"Engineered neutrophil-derived exosome-like vesicles for targeted cancer therapy","volume":"8","author":"Zhang","year":"2022","journal-title":"Sci. Adv."},{"key":"B120","doi-asserted-by":"publisher","first-page":"e28952","DOI":"10.1002\/jmv.28952","article-title":"Synthetic gRNA\/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication","volume":"95","author":"Zhang","year":"2023","journal-title":"J. Med. Virology"},{"key":"B121","doi-asserted-by":"publisher","first-page":"614","DOI":"10.7150\/thno.47007","article-title":"Strategies in the delivery of Cas9 ribonucleoprotein for CRISPR\/Cas9 genome editing","volume":"11","author":"Zhang","year":"2021","journal-title":"Theranostics"},{"key":"B122","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/gt.2015.2","article-title":"Harnessing the clustered regularly interspaced short palindromic repeat (CRISPR)\/CRISPR-associated Cas9 system to disrupt the hepatitis B virus","volume":"22","author":"Zhen","year":"2015","journal-title":"Gene Ther."},{"key":"B123","doi-asserted-by":"publisher","first-page":"258","DOI":"10.14218\/JCTH.2018.00054","article-title":"HBV cccDNA and its potential as a therapeutic target","volume":"7","author":"Zhu","year":"2019","journal-title":"J. Clin. Transl. Hepatology"},{"key":"B124","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.virusres.2016.04.003","article-title":"CRISPR\/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse","volume":"217","author":"Zhu","year":"2016","journal-title":"Virus Res."},{"key":"B125","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jhep.2004.12.015","article-title":"New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA","volume":"42","author":"Zoulim","year":"2005","journal-title":"J. Hepatology"}],"container-title":["Frontiers in Genome Editing"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgeed.2024.1467449\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T04:53:53Z","timestamp":1728449633000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgeed.2024.1467449\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":125,"alternative-id":["10.3389\/fgeed.2024.1467449"],"URL":"https:\/\/doi.org\/10.3389\/fgeed.2024.1467449","relation":{},"ISSN":["2673-3439"],"issn-type":[{"value":"2673-3439","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]},"article-number":"1467449"}}